Business Description
Jazz Pharmaceuticals PLC
NAICS : 325412
SIC : 2834
ISIN : IE00B4Q5ZN47
Compare
Compare
Traded in other countries / regions
JAZZ.USAJ7Z.GermanyJAZZ.Mexico IPO Date
2020-09-02Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.28 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 1.55 | |||||
| Debt-to-EBITDA | 4.72 | |||||
| Interest Coverage | 2.06 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.34 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.4 | |||||
| 3-Year EBITDA Growth Rate | 13.8 | |||||
| 3-Year EPS without NRI Growth Rate | -15.5 | |||||
| 3-Year FCF Growth Rate | 16.5 | |||||
| 3-Year Book Growth Rate | -2.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 3.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -28.37 | |||||
| 12-1 Month Momentum % | -28.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.24 | |||||
| Quick Ratio | 1.85 | |||||
| Cash Ratio | 1.06 | |||||
| Days Inventory | 545.5 | |||||
| Days Sales Outstanding | 61.3 | |||||
| Days Payable | 88.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | 2.5 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.64 | |||||
| Operating Margin % | 15.59 | |||||
| Net Margin % | 10.82 | |||||
| FCF Margin % | 27.5 | |||||
| ROE % | 12.08 | |||||
| ROA % | 3.72 | |||||
| ROIC % | 9.25 | |||||
| ROC (Joel Greenblatt) % | 54.64 | |||||
| ROCE % | 5.89 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.5 | |||||
| Forward PE Ratio | 5.78 | |||||
| PE Ratio without NRI | 11 | |||||
| Shiller PE Ratio | 23.75 | |||||
| Price-to-Owner-Earnings | 20.02 | |||||
| PS Ratio | 2.01 | |||||
| PB Ratio | 1.78 | |||||
| Price-to-Free-Cash-Flow | 7.39 | |||||
| Price-to-Operating-Cash-Flow | 7.1 | |||||
| EV-to-EBIT | 18.46 | |||||
| EV-to-Forward-EBIT | 8.99 | |||||
| EV-to-EBITDA | 8.84 | |||||
| EV-to-Forward-EBITDA | 6.97 | |||||
| EV-to-Revenue | 2.83 | |||||
| EV-to-Forward-Revenue | 2.69 | |||||
| EV-to-FCF | 10.34 | |||||
| Price-to-Projected-FCF | 0.61 | |||||
| Price-to-Median-PS-Value | 0.46 | |||||
| Earnings Yield (Greenblatt) % | 5.42 | |||||
| FCF Yield % | 15.71 | |||||
| Forward Rate of Return (Yacktman) % | 6.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jazz Pharmaceuticals PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 67,145.343 | ||
| EPS (TTM) (MXN) | 106.781 | ||
| Beta | 0.01 | ||
| Volatility % | 28.37 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 0.463932 | ||
| 20-Day SMA (MXN) | 2027.24 | ||
| 12-1 Month Momentum % | -28.37 | ||
| 52-Week Range (MXN) | 2027.24 - 2830 | ||
| Shares Outstanding (Mil) | 62.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jazz Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jazz Pharmaceuticals PLC Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jazz Pharmaceuticals PLC Frequently Asked Questions
What is Jazz Pharmaceuticals PLC(MEX:JAZZ)'s stock price today?
The current price of MEX:JAZZ is MXN2027.24. The 52 week high of MEX:JAZZ is MXN2830.00 and 52 week low is MXN2027.24.
When is next earnings date of Jazz Pharmaceuticals PLC(MEX:JAZZ)?
The next earnings date of Jazz Pharmaceuticals PLC(MEX:JAZZ) is 2024-05-10 Est..
Does Jazz Pharmaceuticals PLC(MEX:JAZZ) pay dividends? If so, how much?
Jazz Pharmaceuticals PLC(MEX:JAZZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers